September 23, 2024
感染症を専門とする公衆衛生専門家と SCARDA 研究者との合同ワクチン国際シンポジウム

Hiroshi Kiyono, D.D.S., Ph.D.

Distinguished Professor, Future Medicine Education and Research Organization, Director, Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University (CU), Chiba, Japan

Co-Director/Adjunct Professor, CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines (cMAV), UC San Diego School of Medicine, San Diego, CA, USA

Dr. Kiyono's background as a dentist combined with his Ph.D in Experimental Pathology and extensive research experience in the field of Mucosal Immunology makes him exceptionally well qualified to discuss the current and future directions of mucosal immunology and mucosal vaccine development. To reflect his scientific contribution, he has published 609 original papers and 144 peer refereed review articles.

2022-Present	Director, cSIMVa, Chiba University
2022-Present	Distinguished Professor, Future Medicine Education and Research Organization and Department of Human Mucosal Vaccinology, Chiba University
2018-Present	Adjunct Professor, Division of Gastroenterology, Department of Medicine and CU-UCSD cMAV, University of California, San Diego
2018-2022	IMSUT Distinguished Professor, Department of Mucosal Immunology, IMSUT Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo (IMSUT)
2018-Present	Professor Emeritus, The University of Tokyo
2011-2019	Director, International Research & Development Center for Mucosal Vaccines, IMSUT
2011-2015	Dean, IMSUT
2002-2018	Professor and Director, Division of Mucosal Immunology, IMSUT
1994-2003	Professor and Chairman, Department of Mucosal Immunology, Research Institute for Microbial Diseases, Osaka University
1991-2003	Professor, Departments of Oral Biology and Microbiology, UAB
1989-1990	Associate Professor, Departments of Oral Biology and Microbiology, UAB
1986-1987	Visiting Senior Scientist, Max-Planck Institute for Biology

①Nakahashi-Ouchida, R., Fujihashi, K., Kurashima, Y., Yuki, Y. and Kiyono, H. 2023. Nasal vaccines: solutions for respiratory infectious diseases. Trends. Mol. Med. 29: 124-140.
②Kamioka, M., Goto, Y., Nakamura, K., Yokoi, Y., Sugimoto, R., Ohira, S., Kurashima, Y., Umemoto, S., Sato, S., Kunisawa, J., Takahashi, Y., Domino, S.E., Renauld, J-C., Nakae, S., Iwakura, Y., Peter B.E., Ayabe, T. and Kiyono, H. 2022. Intestinal commensal microbiota and cytokines regulate Fut2+ Paneth cells for gut defense. Proc. Natl. Acad. Sci. USA. 119: e2115230119.
③Yuki, Y., Nojima, M., Hosono, O., Tanaka, H., Kimura, Y., Satoh, T., Imoto, S., Uematsu, S., Kurokawa, S., Kashima, K., Mejima, M., Nakahashi-Ouchida, R., Uchida, Y., Marui, T., Yoshikawa, N., Nagamura, F., Fujihashi, K. and Kiyono, H. 2021. Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: a phase 1 randomized trial. Lancet Microbe. 2:e429-e440.
④Kurashima, Y., Kigoshi, T., Murasaki, S., Arai, F., Shimada, K., Seki, N., Kim, Y.G., Hase, K., Ohno, H., Kawano, K., Ashida, H., Suzuki, T., Morimoto, M., Saito, Y., Sasou, A., Goda, Y., Yuki, Y., Inagaki, Y., Iijima, H., Suda, W., Hattori, M. and Kiyono, H. 2021. Pancreatic Glycoprotein 2 is a first line of defense for mucosal protection in intestinal inflammation. Nat. Commun. 12:1067.
⑤Goto, Y., Obata, T., Kunisawa, J., Sato, S., Ivanov, I., Lamichhane, A., Takeyama, N., Kamioka, M., Sakamoto, M., Matsuki, T., Setoyama, H., Imaoka, A., Uematsu, S., Akira, S., Domino, S., Kulig, P., Becher, B., Renauld, J-C., Sasakawa, C., Umesaki, Y., Benno, Y. and Kiyono, H. 2014. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science. 345: 1254009. (Article)